Disease · MONDO_0005027
Comparisons in its trials91
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 91
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects Who Withdraw From the Study Due to a Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks) | 47 of 444 | 69 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (up to 113 Weeks) | 328 of 444 | 332 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): Number of Subjects With at Least One Treatment-emergent Serious Adverse Event (SAE) During the Treatment Phase (up to 113 Weeks) | 32 of 444 | 43 of 442 | 886 | NCT01243177 | Trial comparisons |
| Lacosamide vs Carbamazepine-Controlled Release (CBZ-CR): serious adverse events | 36 of 444 | 46 of 442 | 886 | NCT01243177 | Trial comparisons |
| Brivaracetam vs Placebo: serious adverse events | 20 of 359 | 9 of 121 | 480 | NCT00504881 | Trial comparisons |
| Levetiracetam (Safety Set) vs Carbamazepine-IR (Safety Set): serious adverse events | 9 of 218 | 11 of 215 | 433 | NCT01954121 | Trial comparisons |
| Rufinamide vs Placebo: deaths from any cause | 0 of 176 | 0 of 180 | 356 | NCT00334958 | Trial comparisons |
| Rufinamide vs Placebo: serious adverse events | 6 of 176 | 7 of 180 | 356 | NCT00334958 | Trial comparisons |
| Vimpat + Na Channel Blocking AED vs Vimpat + Non-Na Channel Blocking AED: serious adverse events | 1 of 153 | 6 of 158 | 311 | NCT01673282 | Trial comparisons |
| Melatonin vs Placebo: deaths from any cause | 0 of 137 | 0 of 138 | 275 | NCT05439876 | Trial comparisons |
| Melatonin vs Placebo: serious adverse events | 0 of 137 | 0 of 138 | 275 | NCT05439876 | Trial comparisons |
| Intravenous Carbamazepine (IV CBZ) 15 Minutes Infusion vs Intravenous Carbamazepine (IV CBZ) 5 Minutes Infusion: serious adverse events | 2 of 105 | 0 of 101 | 206 | NCT01128959 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Retention Rate After 52 Weeks Maintenance Period | 104 of 104 | 98 of 98 | 202 | NCT00807989 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: serious adverse events | 9 of 104 | 0 of 98 | 202 | NCT00807989 | Trial comparisons |
| Zonisamide vs Carbamazepine: serious adverse events | 5 of 96 | 9 of 104 | 200 | NCT01127256 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 52 Weeks at Initial Target Dose | 43 of 90 | 50 of 78 | 168 | NCT00807989 | Trial comparisons |
| Carbamazepine vs Lamotrigine/Valproate: Seizure Free Rate for 24 Weeks at Initial Target Dose | 51 of 90 | 59 of 78 | 168 | NCT00807989 | Trial comparisons |
| Diazepam vs Placebo: Number of Participants Requiring Rescue Medication During the Double-blind Period | 14 of 82 | 24 of 81 | 163 | NCT00319501 | Trial comparisons |
| Diazepam vs Placebo: Number of Participants Requiring Rescue Medical Care Other Than Rescue Medication or Emergency Department Visits During the Double-blind Period | 0 of 82 | 2 of 81 | 163 | NCT00319501 | Trial comparisons |
| Diazepam vs Placebo: Number of Participants Requiring Emergency Department Visits During the Double-blind Period | 2 of 82 | 4 of 81 | 163 | NCT00319501 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005027/comparisons